Dear Wealth Daily reader:

"Behind every story is a Greek man."

That was Dr. Khan's response when I asked her why she left the prominent biotechnology industry in England to join Anavex Life Sciences in Greece.

Indeed, she was right.

The man behind the Anavex story is Dr. Alexandre Vamvakides. And when it comes to biotechnology research and reputation, he's a giant among his peers.

Dr. Vamvakides has literally spent the last 30 years in research, focusing on finding a cure for diseases of the central nervous system (CNS). He has published over 80 scientific papers in medical journals... and is considered one of the pioneers and foremost experts in the emerging field of sigma receptors.

Let me be very clear about this: All of his experience and expertise is about to explode onto the market at a single moment in history - when his Alzheimer drug - AV 1-41 - goes into Phase I later this year.

You see, Dr. Vamvakides and Anavex are developing the next generation of biotech drugs based on a platform that focuses on sigma receptors.

Sigma receptors are a new class of receptors that have been identified with significant links to various diseases.

I consider the work being done on sigma receptors similar to the work that was done on stem cells 10 to 15 years ago.

This is going to be huge.

There's a massive amount of literature that supports sigma receptors as a potential way to treat... and in some cases prevent... of a whole range of diseases, including Alzheimer and epilepsy to breast and lung cancer.

In other words, we could be looking at a silver bullet in biotechnology.

Now, I'm not going to get into the science behind sigma receptors and the drugs being developed. It's just too technical. (To get the full details on the preclinical results, call Anavex's Investor Relations department at 1-866-505-2895 and request to receive an IR kit. Plus, I'll be publishing a full report on the company's pipeline in the days to come.)

I just want you to understand that Anavex is emerging as a major player within this field of research.

In a press release last month, Anavex reported...

"...that ANAVEX 7-1037 has demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies. It reduced tumor growth by 69% with minimal side effects."

These results put Anavex on the map.

In fact, Dr. Vamvakides and Anavex are starting to attract institutional money managers... and the company will be presenting at some of the most important biotechnology conferences in the world.

And that's one of the reasons why I quickly hopped on a plane and flew to Athens, Greece, last week. Anavex will be presenting at the Rodman & Renshaw Annual Global Healthcare conference in Monaco on May 19. (hyper link to this site: http://www.rodmanandrenshaw.com/conferences?id=18)

Over 1,000 money managers and investors will be in attendance at the May conference. That's a month away. I want to position you with Anavex stock before Wall Street begins taking out big blocks.

You see, I think Anavex is going to run up like another biotechnology that's almost identical to its situation. It's a company called Medivation, who's pushing its own Alzheimer drug through the clinic, and is now in Phase III.

Medivation started trading on the OTC bulletin board in 2004. It then jumped to the NASDAQ:

After successfully getting its Alzheimer drug Dimebon through pre-clinical and into Phase I and II, Medivation's stock took off. At one point late last year, Medivation's market cap mushroomed to nearly $1 billion, even though it didn't have a drug on the market.

Anavex plans to have its own Alzheimer drug - Anavex 1-41 - in Phase I within the next 6 months.

When AV-1-41 goes into Phase I trials, I fully expect the market to re-rate the company upwards to $10 to $12 a share.

I continue to rate Anavex stock as one of my favorite small cap investments for 2008-2009. And the fact that the stock hasn't sold off - especially during the recent market turmoil - speaks volumes.

I believe we're looking at a huge blockbuster in Anavex Life Sciences (AVXL - OTCBB). Buy it at current levels.

Good investing,

Brian Hicks

P.S. I spent a full week in Athens, and spent 3 days with the researchers at Anavex. I'll have a full report on the company and its pipeline in the coming days. Stay tuned...